KCM
MACK

Kennedy Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Kennedy Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-46,202
Closed -$620K – 787
2023
Q4 		$620K Sell
46,202
-47,506
-51% -$600K 0.01% 626
2023
Q3 		$1.16M Buy
93,708
+2,202
+2% +$26.7K 0.03% 549
2023
Q2 		$1.13M Buy
91,506
+77,748
+565% +$972K 0.03% 543
2023
Q1 		$169K Buy
+13,758
New +$162K 0.01% 607

Other funds holding MACK

WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's MACK Position: Q1 2024 in Review

Kennedy Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2024, closing a stake of 46,202 shares — an estimated $620K sold.

Kennedy Capital Management first reported a position in MACK in Q1 2023 and held it in 4 quarters. The position peaked at $1.16M in Q3 2023. 70 funds tracked by Wall St. Rank hold MACK as of Q1 2024.

  • Kennedy Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 46,202 Merrimack Pharmaceuticals, Inc. shares in Q1 2024, an estimated $620K.
  • Kennedy Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2023 and held it in 4 quarters.
  • Kennedy Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $1.16M in Q3 2023.
  • 70 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2024.

Based on Kennedy Capital Management's 13F filing for Q1 2024, filed 15 May 2024.